{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:28:10Z","timestamp":1761895690437,"version":"3.40.4"},"reference-count":15,"publisher":"Cambridge University Press (CUP)","issue":"2","license":[{"start":{"date-parts":[[2013,5,9]],"date-time":"2013-05-09T00:00:00Z","timestamp":1368057600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":["journals.cambridge.org"],"crossmark-restriction":true},"short-container-title":["Epidemiol. Infect."],"published-print":{"date-parts":[[2014,2]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p>Antibiotic susceptibilities of large cohorts of Enterobacteriaceae isolated from urine collected in the community are scarce. We report the susceptibilities of Enterobacteriaceae isolated from urine of non-selected community populations in a metropolitan area (Leeds and Bradford, UK) over 2 years. Isolates (<jats:italic>n<\/jats:italic>\u00a0=\u00a06614) were identified as follows:<jats:italic>Escherichia coli<\/jats:italic>(<jats:italic>n<\/jats:italic>\u00a0=\u00a05436),<jats:italic>Klebsiella<\/jats:italic>spp. (<jats:italic>n<\/jats:italic>\u00a0=\u00a0525),<jats:italic>Proteus mirabilis<\/jats:italic>(<jats:italic>n<\/jats:italic>\u00a0=\u00a0305), and 15 other species (<jats:italic>n<\/jats:italic>\u00a0=\u00a0290); 58 isolates were unidentified. Ampicillin resistance was observed in 53%<jats:italic>E. coli<\/jats:italic>and 28%<jats:italic>P. mirabilis<\/jats:italic>; \u2a7e34%<jats:italic>E. coli<\/jats:italic>and<jats:italic>P. mirabilis<\/jats:italic>were non-susceptible to trimethoprim compared to 20%<jats:italic>Klebsiella<\/jats:italic>spp.; nitrofurantoin resistance was observed in 3%<jats:italic>E. coli<\/jats:italic>and 15%<jats:italic>Klebsiella<\/jats:italic>spp. The occurrence of extended-spectrum<jats:italic>\u03b2<\/jats:italic>-lactamases (ESBL) was low (6%), as was non-susceptibility to carbapenems, cefipime and tigecycline (&lt;2%). Further surveillance is required to monitor this level of resistance and additional clinical studies are needed to understand the impact on the outcome of current empirical prescribing decisions.<\/jats:p>","DOI":"10.1017\/s0950268813000988","type":"journal-article","created":{"date-parts":[[2013,5,9]],"date-time":"2013-05-09T09:36:22Z","timestamp":1368092182000},"page":"399-403","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":17,"title":["Surveillance of antibiotic susceptibility of Enterobacteriaceae isolated from urine samples collected from community patients in a large metropolitan area, 2010\u20132012"],"prefix":"10.1017","volume":"142","author":[{"given":"C. S.","family":"HORNER","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"ABBERLEY","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"DENTON","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. H.","family":"WILCOX","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2013,5,9]]},"reference":[{"key":"S0950268813000988_ref13","unstructured":"Health Protection Agency. Management of infection guidance for primary care for consultation and local adaptation (http:\/\/www.hpa.org.uk\/webc\/HPAwebFile\/HPAweb_C\/1194947333801). Accessed 24 April 2013."},{"key":"S0950268813000988_ref10","first-page":"177","article-title":"Epidemiology and resistance patterns in urinary pathogens from long-term care facilities and GP populations","volume":"105","author":"Brabazon","year":"2012","journal-title":"Irish Medical Journal"},{"key":"S0950268813000988_ref7","doi-asserted-by":"publisher","DOI":"10.3109\/00365548.2011.623314"},{"key":"S0950268813000988_ref2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00688-09"},{"key":"S0950268813000988_ref4","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh424"},{"key":"S0950268813000988_ref15","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl432"},{"key":"S0950268813000988_ref12","unstructured":"Heginbothom M , Howe R . Antibacterial resistance and usage in Wales, 2005\u20132010. 2011 (http:\/\/www.wales.nhs.uk\/news\/21018). Accessed 13 December 2012."},{"key":"S0950268813000988_ref6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25532"},{"key":"S0950268813000988_ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2007.01867.x"},{"key":"S0950268813000988_ref8","unstructured":"European Centre for Disease Prevention and Control. European Antimicrobial Resistance Surveillance System (EARSS-Net) (http:\/\/www.rivm.nl\/earss\/). Accessed 26 November 2012."},{"key":"S0950268813000988_ref9","first-page":"ii41","article-title":"Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001\u201306","volume":"62","author":"Livermore","year":"2008","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"S0950268813000988_ref3","unstructured":"Health Protection Agency. Department of Health Advisory Committee on Antimicrobial Resistance and Hospital Associated Infection (ARHAI). Advice on carbapenemase producers: recognition, infection control and treatment (http:\/\/www.hpa.org.uk\/Topics\/InfectiousDiseases\/InfectionsAZ\/CarbapenemResistance\/GuidanceOnCarbapenamProducers\/). Accessed 24 April 2013."},{"key":"S0950268813000988_ref1","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2010.190"},{"key":"S0950268813000988_ref11","doi-asserted-by":"publisher","DOI":"10.1053\/jinf.2002.1091"},{"key":"S0950268813000988_ref14","doi-asserted-by":"crossref","unstructured":"Health Protection Agency. Clostridium difficile infection: how to deal with the problem (http:\/\/www.hpa.org.uk\/webc\/HPAwebFile\/HPAweb_C\/1232006607827). Accessed 24 April 2013.","DOI":"10.1016\/j.anaerobe.2013.01.006"}],"container-title":["Epidemiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0950268813000988","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T09:20:46Z","timestamp":1746004846000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0950268813000988\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,9]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0950268813000988"],"URL":"https:\/\/doi.org\/10.1017\/s0950268813000988","relation":{},"ISSN":["0950-2688","1469-4409"],"issn-type":[{"type":"print","value":"0950-2688"},{"type":"electronic","value":"1469-4409"}],"subject":[],"published":{"date-parts":[[2013,5,9]]},"assertion":[{"value":"Copyright \u00a9 Cambridge University Press 2013\u00a0","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}}]}}